Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

A retrospective study of an artificial intelligence program for reading 3D mammography scans illustrated the pros, cons and ...

Days after the Women’s Health Initiative, one of the largest and longest women’s health studies in the world, announced that ...

Big Pharmas aren’t letting the looming threat of potential tariffs divert them from their M&A strategies for the year—at ...

Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will ...

Over the next four months, the Vaccine Integrity Project will hold information-gathering sessions with medical associations, ...

The pipeline purge comes less than a year after Caribou cut 12% of staff and ended its natural killer cell therapy program in ...

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the ...

Big Pharma's M&A plans will likely take a hit if the U.S. government under the Trump administration lives up to its threats ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...